Treatment of Alzheimer's disease: current and future therapeutic approaches
- PMID: 16400259
Treatment of Alzheimer's disease: current and future therapeutic approaches
Abstract
The pathophysiology of Alzheimer's disease (AD) includes the deposition of amyloid beta protein (Abeta) and the ensuing initiation of a variety of secondary processes, including tau hyperphosphorylation, excitotoxicity, oxidation, and inflammation. Nerve cell loss in structures responsible for manufacturing neurotransmitters results in a variety of neurochemical deficits. Current therapeutic approaches to the treatment of AD include cholinesterase inhibitors for mild to moderate disease, memantine for moderate to severe disease, and vitamin E or selegiline. Reduction of Abeta generation or aggregation, enhancement of Abeta removal, interruption of tau hyperphosphorylation, and the use of more efficacious antioxidant or anti-inflammatory agents represent promising therapeutic strategies currently being investigated. Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD.
Similar articles
-
[Therapy of Alzheimer disease].Neuropsychopharmacol Hung. 2009 Mar;11(1):27-33. Neuropsychopharmacol Hung. 2009. PMID: 19731816 Review. Hungarian.
-
Current and future therapy in Alzheimer's disease.Fundam Clin Pharmacol. 2008 Jun;22(3):265-74. doi: 10.1111/j.1472-8206.2008.00578.x. Fundam Clin Pharmacol. 2008. PMID: 18485144 Review.
-
[Alzheimer's disease: from brain lesions to new drugs].Bull Acad Natl Med. 2008 Feb;192(2):363-78; discussion 378-80. Bull Acad Natl Med. 2008. PMID: 18819689 Review. French.
-
[New therapeutic options in Alzheimer's disease].Rev Neurol. 2006 Apr 16-30;42(8):478-81. Rev Neurol. 2006. PMID: 16625510 Review. Spanish.
-
Current approaches in the treatment of Alzheimer's disease.Biomed Pharmacother. 2008 Apr-May;62(4):199-207. doi: 10.1016/j.biopha.2008.02.005. Epub 2008 Mar 17. Biomed Pharmacother. 2008. PMID: 18407457 Review.
Cited by
-
Eugenol Attenuates Scopolamine-Induced Hippocampal Cholinergic, Glutamatergic, and Mitochondrial Toxicity in Experimental Rats.Neurotox Res. 2019 May;35(4):848-859. doi: 10.1007/s12640-019-0008-6. Epub 2019 Feb 9. Neurotox Res. 2019. PMID: 30737653
-
Therapeutics with SPION-labeled stem cells for the main diseases related to brain aging: a systematic review.Int J Nanomedicine. 2014 Aug 11;9:3749-70. doi: 10.2147/IJN.S65616. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25143726 Free PMC article.
-
Reduced Alzheimer's disease pathology by St. John's Wort treatment is independent of hyperforin and facilitated by ABCC1 and microglia activation in mice.Curr Alzheimer Res. 2013 Dec;10(10):1057-69. doi: 10.2174/15672050113106660171. Curr Alzheimer Res. 2013. PMID: 24156265 Free PMC article.
-
Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.J Mol Model. 2017 Feb;23(2):67. doi: 10.1007/s00894-017-3228-9. Epub 2017 Feb 9. J Mol Model. 2017. PMID: 28185116
-
Behavioral and psychological symptoms of dementia.Front Neurol. 2012 May 7;3:73. doi: 10.3389/fneur.2012.00073. eCollection 2012. Front Neurol. 2012. PMID: 22586419 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical